{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001689","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.233028+00:00","generated_at":"2026-05-24T05:48:32.993917+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus reports Q4 net loss $12.1M, cash $52M; atopic dermatitis Phase 1 shows 37% EASI 75 vs 0% placebo","bullets":["Net loss for Q4 2024 was $12.1M vs $6.7M in Q4 2023; full-year R&D expense $19.4M.","Cash, equivalents and securities $52.0M as of Dec 31, 2024, up from $27.1M, with runway into Q1 2026.","Atopic dermatitis Phase 1 cohorts 1-2: 26% of soquelitinib patients achieved IGA 0/1, 37% EASI 75 vs 0% placebo.","Phase 3 registrational trial of soquelitinib in PTCL is enrolling; Phase 2 ALPS trial initiated under NIAID.","Approximately $18.6M cash from early exercise of 5.3M warrants; 11.8M warrants remain outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001689","json":"https://secwatch.observer/filing/0001171843-25-001689.json","markdown":"https://secwatch.observer/filing/0001171843-25-001689.md","text":"https://secwatch.observer/filing/0001171843-25-001689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/0001171843-25-001689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325001689/f8k_032525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:48:32.993917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}